Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

Hepatology

Volumn 31, Issue 1, 2000, Pages 207-210

  Villeneuve, Jean Pierre ^a,e   Condreay, Lynn D ^b   Willems, Bernard ^a   Pomier Layrargues, Gilles ^a   Fenyves, Daphna ^a   Bilodeau, Marc ^a   Leduc, Raymond ^a   Peltekian, Kevork ^c   Wong, Florence ^d   Margulies, Mariana ^d   Heathcote, E Jenny ^d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b GLAXOSMITHKLINE   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 17544369393     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510310130     Document Type: Article

References (13)

1. DeJongh FE, Janssen HLA, DeMan LA, Hop WCJ, Schalm SW, Van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-1635.
2. Nevens F, Goubau P, Van Eyken P, Desmyter J, Desmet V, Fevery J. Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver 1993;13:15-19.
3. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alpha for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993;104:1116-1121.
4. Perillo R, Tamburro C, Regenstein F, Bolart L, Bodenheimer H, Suva M, Schiff E, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995;109:908-916.
5. Marcellin P, Giuily N, Loriot MA, Durand F, Samuel D, Bettan L, Degott C, et al. Prolonged interferon-alpha therapy of hepatitis B virus-related decompensated cirrhosis. J Viral Hepatitis 1997;4(Suppl 1):21-26.
6. Dienstag JL, Perillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
7. Nevens F, Main F, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258-1263.
8. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
9. Perillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, Dienstag J, et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation (OLT) [Abstract]. HEPATOLOGY 1997;26: 315A.
10. Van Thiel DH, Friedland L, Kania RJ, Molloy PJ, Hassaneim E, Faruki H. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepato-Gastroenterology 1997;44:808-812.
11. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
12. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. HEPATOLOGY 1998;27:628-633.
13. Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Kato J, Carilloho FJ, et al. Susceptibility of lamivudine resistant hepatitis B virus to other antivirals: adefovir and lobucavir. HEPATOLOGY 1998;28:165A.